TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China

SUZHOU, China, Dec. 2, 2021 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHARM, 1875.HK) announced its self-developed Pusintin® (TAB008, bevacizumab injection) has been officially granted approval by the National Medical Products Administration ("NMPA") for marketing in main...

2021-12-02 08:00 1398

TOT BIOPHARM Anounces 2021 Interim Results

Revenue Surges 78% to RMB23.13 million CDMO Business Achieves Leapfrog Breakthrough Two Products Approved for Launch Smooth Progress of Various Core Anti-tumor Drugs Clinical Trials To Allocate Resources to Boost Innovative ADC Drugs HONG KONG and SUZHOU, China, Aug. 13, 2021 /PRNewswire/ -- TOT B...

2021-08-13 10:59 18276

TOT BIOPHARM (1875.HK) Proceeded with IPO raising over HK$500 million

HONG KONG, Nov. 7, 2019 /PRNewswire/ -- A clinical-stage biopharmaceutical company with full industry value chain capabilities, TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company", together with its subsidiaries, the "Group", stock code: 1875) was well received by the capi...

2019-11-07 19:04 6280